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Abstract: Viral neuraminidase inhibitors such as oseltamivir and zanamivir prevent early 
virus multiplication by blocking sialic acid cleavage on host cells. These drugs are effective 
for the treatment of a variety of influenza subtypes, including swine flu (H1N1). The binding 
site for these drugs is well established and they were designed based on computational docking 
 studies. We show here that some common natural products have moderate inhibitory activity 
for H1N1 neuraminidase under docking studies. Significantly, docking studies using AutoDock 
for biligand and triligand forms of these compounds (camphor, menthol, and methyl salicylate 
linked via methylene bridges) indicate that they may bind in combination with high affinity to 
the H1N1 neuraminidase active site. These results also indicate that chemically linked biligands 
and triligands of these natural products could provide a new class of drug leads for the preven-
tion and treatment of influenza. This study also highlights the need for a multiligand docking 
algorithm to understand better the mode of action of natural products, wherein multiple active 
ingredients are present.
Keywords: neuraminidase, influenza, H1N1, multiligand, binding energy, molecular docking, 
virus
Introduction
Hemagglutinin and neuraminidase are the two key glycoproteins responsible for viral 
influenza infection.1 Hemagglutinin is present on the surface of the virion and is needed 
for infection, while neuraminidase is responsible for cleavage of sialic acid (neuraminic 
acid) from glycans of the infected cell.2,3 These two proteins are drug targets for viral 
infections, and the neuraminidase inhibitors, oseltamivir (Tamiflu®, Roche, Basel, 
Switzerland) and zanamivir (Relenza®, Philadelphia, PA, USA), are broad spectrum 
antiviral drugs, useful for the treatment of a variety of forms of influenza.4,5 The 
World Health Organization recommends the use of oseltamivir or zanamivir for the 
treatment of H1N1 virus, and patient recovery with these drugs has been impressive. 
Oseltamivir and zanamivir are reversible competitive inhibitors of neuraminidase, 
thereby preventing virion release from infected cells.6 The binding site interaction of 
these drugs is well established, and they are amongst only a few drugs with binding 
sites based on computational docking and quantitative structure-activity relationships 
that are well understood.
The success of neuraminidase inhibitors can be attributed to the sequence and struc-
ture conservation of neuraminidase in all subtypes of influenza. Reports of mutations 
in neuraminidase are relatively sparse compared with other viral protein domains.1 
There are significant changes in both hemagglutinin and neuraminidase protein of the 
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2012 H1N1 virus, ie, 27.2% and 18.2% of the amino acid 
sequence, respectively, from 2008 H1N1 isolates.1 Though 
these changes are a complication with respect to the use of 
existing influenza vaccines, the positive response of this virus 
to current neuraminidase inhibitors indicates that this change 
does not significantly alter the protein-ligand interactions.
Hence, neuraminidase is an excellent general target for the 
control of viral influenza, including H1N1. Although neuramini-
dase inhibitors such as oseltamivir and zanamivir are approved 
for both treatment and prevention of influenza, more effective 
preventive medications would be useful in slowing the spread 
of H1N1 influenza.4,7 Therefore, there is a need to develop 
improved drugs which can prevent the spread of the virus.
There are several common cold medications which have 
been available for generations to provide relief from symp-
toms, including sneezing, blocked nose, sore throat, and nasal 
congestion. They include over-the-counter products (such as 
inhalers and vaporizers) and homemade decoctions of spices 
(eg, ginger, pepper, basil). Most of these have a pungent aro-
matic odor and the exact mechanism of action of their active 
constituents is unknown. The effectiveness of these compounds 
in relieving symptoms caused by influenza warrants further 
investigation into whether any of this efficacy comes from 
specific binding mechanisms. If these compounds selectively 
bind to specific targets then they could potentially be used more 
broadly in H1N1 influenza prevention or treatment.
Materials and methods
The Protein Data Bank crystal structure (2hu0) of the 
neuraminidase in H5N1 bound to oseltamivir was used as a 
reference8 and a model built for H1N1 neuraminidase was 
used for docking studies.9 AutoDock10 (The Scripps Research 
Institute, La Jolla, CA, USA) was used for protein-ligand 
docking studies. Chemical structures were downloaded from 
Pubchem and similar databases and  verified or drawn using 
ACD Chemsketch (Advanced Chemistry Development, Inc., 
Toronto, ON, Canada) Protein electrostatic potential was cal-
culated using the Adaptive Poisson Boltzmann Solver (ABPS) 
with AutoDockTools release 1.5.4.10 Molecular graphics 
images were produced using the UCSF Chimera package from 
the Computer Graphics Laboratory, University of California, 
San Francisco, CA, USA.11
Results and discussion
neuraminidase structure selection  
and protein model
Maurer-Stroh et al have demonstrated that the neuramini-
dase present in current variants of H1N1 is similar to that 
present in H5N1 avian influenza.9 The crystal structure of 
neuraminidase in H5N1 bound to oseltamivir is known and 
we used this as a reference structure for our study. Maurer-
Stroh et al built a model for H1N1 based on the previously 
reported information for H5N1, and we used the same model 
after ensuring that the crystal structure of neuraminidase 
in H5N1 and H1N1 is similar (root-mean-square deviation 
0.81 Å). Figure 1 shows the overlay of H5N1 and H1N1 
neuraminidase structures. Recent crystal structures of some 
strains of H1N1 neuraminidase, such as the 1918 influenza 
viral strain, indicate that there is a high degree of structural 
similarity to the H5N1 strain. Both are group 1 subtypes 
characterized by a similar conformation for the 150 loop 
or 150 cavity which, on binding to zanamivir, undergoes 
conformational change that is similar for both H1N1 and 
H5N1 subtypes.12
Binding site of h1n1 neuraminidase
The binding site of neuraminidase is a conserved region 
in different variants of influenza A and B. The key step 
of viral attack and multiplication in the host cell is driven 
by binding of viral neuraminidase to sialic acid on the 
human cell surface.3 Hence, the inhibitors of neuraminidase 
 (oseltamivir and zanamivir) are designed in such a way that 
they are chemically as similar as possible to sialic acid, with 
improved enzyme affinity. Figure 2 shows the binding site 
of H1N1 neuraminidase, depicting the two different electro-
static grooves as A and B, representing two complementary 
regions, a highly negatively charged region (depicted by red 
color), and a positively charged stretch. Under docking condi-
Figure 1 Overlay of h5n1 crystal structure (2hu0, yellow) and the modeled 
structure of h1n1 (red). The root-mean-square deviation of the two structures 
is 0.81 Å.
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Figure 2 Picture depicting the two regions of the h1n1 neuraminidase 
binding site. The red region (A) is the electronegative region, where the 
amine-rich functional groups of ligands bind, and the large blue region (B) a 
large electropositive zone. The deep binding pocket (A) could host many kinds 
of ligands, but high affinity can be obtained only when there is a well defined 
functional group interaction (electrostatic and/or structural).
tions, sialic acid has the possibility of nine hydrogen bonds 
at the A binding site and synthetic inhibitors like oseltamivir 
and zanamivir have about seven. Important aspects for the 
H1N1 neuraminidase quantitative structure-activity rela-
tionship are the electrostatic interaction between ligand and 
protein, and the possible formation of salt bridges between 
the amine-rich terminus of the ligand and glutamic acid in 
the binding site. This kind of ligand design is dependent on 
interaction between the binding site amino acid residues and 
the ligand, and is probably a reason why oseltamivir-resistant 
strains have started to evolve.13–15
Binding of oseltamivir and sialic acid  
to h1n1 neuraminidase
Oseltamivir is one of the few inhibitors of neuraminidase with 
subnanomolar affinity and currently in clinical use for the 
treatment of influenza.16 In our docking mode, oseltamivir is 
the strongest ligand of those studied (Table 1), with the lowest 
docking energy of −13.94 kcal/mol. The predicted binding 
constant for oseltamivir is at least 10 times higher than that 
for sialic acid (Figure 3). The hydrogen bond-rich interac-
tion of sialic acid has not resulted in higher binding affinity. 
The higher affinity of oseltamivir is probably related to salt 
bridge formation (Figure 4). In our analysis, zanamivir had 
a binding affinity similar to that of sialic acid, with docking 
energy of −12.84 kcal/mol (Table 1).
Zanamivir also forms a binding site salt bridge and has 
seven hydrogen bonds possible at the binding site. The sig-
nificantly higher binding affinity of oseltamivir as compared 
Table 1 Docking energies (affinity) for different chemicals with 
h1n1 neuraminidase
Compound name Docking energy 
(kcal/mol)
1 Oseltamivir −13.94
2 Zanamivir −12.84
3 Methyl salicylate-menthol-camphor −12.68
4 sialic acid −12.47
5 Camphor-methyl salicylate-menthol −12.02
6 Oleanolic acid −11.74
7 rosmarinic acid −11.71
8 Methyl salicylate-camphor-menthol −11.18
9 Carnosic acid −10.49
10 Capsaicin −10.3
11 gingerol −9.97
12 rosmanol −9.67
13 Camphor-menthol −9.31
14 Chlorogenic acid −9.09
15 Caryophyllene −8.51
16 Piperine −8.43
17 Zingiberene −7.81
18 geraniol −7.06
19 hydroxycitric acid −6.98
20 Bisabolol −6.64
21 β-Terpineol −6.62
22 Borneol −6.61
23 eugenol −6.45
24 linalool −6.27
25 Ascorbic acid −6.23
26 Camphor −6.15
27 Thymol −6.14
28 Cineole −6.12
29 Methyl salicylate −5.8
30 γ-Terpinene −5.74
31 Menthol −5.73
32 Thymoquinone −5.39
33 Cinnamaldehyde −5.32
with zanamivir, even though both have a similar number of 
hydrogen bonds and form salt bridges, indicates that there 
may be a structural parameter that impacts binding that was 
not determined in previous studies.14,15,17
Docking of natural product chemical 
constituents
We docked the three major chemical constituents of common 
inhalers, namely menthol, camphor, and methyl salicylate. 
These components as well as antioxidants (rosemary oil 
components), traditional cold medicines (ginger, pepper) and 
common natural essential oil products have shown significant 
affinity for H1N1 neuraminidase (Table 1). Surprisingly, we 
observed that a steroid molecule (oleanolic acid) present in 
rosemary extract has high affinity for H1N1 neuraminidase 
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edge, there is no docking program which allows multiple 
ligand docking. Simultaneous binding of ligands to the same 
target is an unusual concept, but it has been used in biligand 
design for some protein targets, such as oxidoreductases.20 
This approach uses docking and nuclear magnetic resonance 
studies for two compounds binding next to each other, using 
NOE determined distances to show the spatial relationship 
between each compound. A new compound containing both 
molecular structures can then be synthesized and tested 
for binding affinity. This biligand approach has resulted in 
some clinical leads and the linking of two active compounds 
through methylene groups has shown some success. In the 
case of H1N1 neuraminidase, the binding site is so large 
that it can readily accommodate more than one ligand. 
Neuraminidase is similar to oxidoreductase in that both have 
two binding sites A and B adjacent to each other.21
We hypothesized that if a ligand was structurally con-
nected through a methylene group at the methyl terminus of 
a molecule it should provide a dockable biligand with suf-
ficient flexibility due to two additional single bonds, which 
could mimic the simultaneous binding of two ligands. Among 
the functional groups commonly present in both natural and 
synthetic inhibitors, methyl groups are physiologically the 
least relevant due to their small size and lack of chemical 
functionality. Methylene linking has been successfully used 
in biligand development for oxidoreductases and binding 
shown to occur using nuclear magnetic resonance. The 
methylene group itself has minimal impact on binding and 
the methylenes primarily enable flexibility in orientation 
of the biligands. Hence, conjugation to a terminal methyl 
group may not significantly change the affinity of the original 
ligand. Secondly, when two molecules are chemically linked, 
the degrees of freedom for rotation decreases, which could 
affect the docking results, in that docking software may not 
be able to test all possible orientations. By bridging methyl 
groups of ligands with a methylene group, we created two 
extra rotatable bonds, which compensates for the loss of 
degrees of freedom. Finally, introduction of an extra methyl-
ene functional group creates an average 3 Å distance between 
molecules, which is the minimum distance two molecules 
are expected to maintain when they are bound together in 
solid state to a target.
The first combination ligand we designed was camphor-
menthol. This molecule is predicted to bind with a docking 
energy of −9.31 kcal/mol, which is about 1000-fold higher than 
the affinity of each individual chemical component. This com-
bination molecule formed only one hydrogen bond, indicating 
that structural affinity rather than electrostatic interaction is 
Figure 4 Model showing docked configuration of oseltamivir with h1n1 
neuraminidase.
Figure 3 Model showing docked configuration of sialic acid with h1n1 neuraminidase.
(−11.74 kcal/mol). Oleanolic acid does not bind with as many 
hydrogen bonds as sialic acid and oseltamivir, indicating that 
it has a structural specificity for the neuraminidase binding 
site. Cold and influenza relief recipes used in traditional 
Indian medicine are general decoctions of herbs and often 
use cocktails containing multiple ingredients.18,19 These 
would have multiple active components, which may have 
cumulative or synergistic actions. Based on this, we evalu-
ated the binding of some of these compounds in combination. 
Since the docking software accepts only one molecule at a 
time, we evaluated the combination effect using a “linked-
structure” approach. As seen in Table 1, these combination 
linked structures had significantly higher binding affinities 
than the individual molecules.
Multiligand binding: linked structure 
approach
Of the natural products evaluated, the most potent H1N1 
neuraminidase binders in our model were oleanolic acid 
and rosmarinic acid. It is possible that multiple components 
could simultaneously bind to the of H1N1 neuraminidase. 
 AutoDock does not allow multiple ligands to be docked with 
the same protein at the same time. To the best of our knowl-
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Figure 5 Chemical structure of combination ligands. Methyl salicylate-menthol-camphor (A), methyl salicylate-camphor-menthol (B), and camphor-methyl 
salicylate-menthol (C). The arrows show the methylene bridges artificially created to enable the possibility of docking the combination ligand with the enzyme. Note the drop 
in docking energy of B (−11.18 kcal/mol) when menthol and camphor position is interchanged from A (−12.68).
Figure 6 Docking of methyl salicylate-menthol-camphor to neuraminidase enzyme. Figure 7 Docking of methyl salicylate-camphor-menthol with neuraminidase.
primarily responsible for the increased binding affinity. We then 
designed a triligand comprising menthol, camphor, and methyl 
salicylate, with three possible structural forms. We followed 
the methylene linking strategy in designing these molecules, 
and they were methyl salicylate-menthol-camphor, methyl 
salicylate-camphor-menthol, and camphor-methyl salicylate-
menthol (Figure 5). We observed that all three combination 
ligands had good affinity for H1N1 neuraminidase, but the 
mode and orientation of binding was different. Among these, 
methyl salicylate-menthol-camphor had the highest affin-
ity, which was almost the same as sialic acid and zanamivir 
(Table 1). The binding of methyl salicylate-menthol-camphor 
resembles a triangular structure covering the electronegative 
pocket in the binding region (Figure 6). Importantly, the methyl 
salicylate-menthol-camphor is bound completely at the A site 
and no part of the molecule was interacting with the B site. 
This indicates that the interaction of this ligand with H1N1 
neuraminidase has a strong structural basis.
In the case of methyl salicylate-camphor-menthol 
 (Figure 7), the menthol group occupied the B site. This is 
in contrast with methyl salicylate-menthol-camphor, where 
there was a specific stabilizing interaction with the A bind-
ing site (Figure 6). This specific interaction was absent with 
methyl salicylate-camphor-menthol and may be responsible 
for the lower docking energy of this triligand (−11.18 versus 
−12.68 kcal/mol, refer to Table 1).
The difference in affinity of other combination ligands 
with respect to methyl salicylate-menthol-camphor suggests 
that there could be specific structural sites for the three 
ligands, and interchanging their position in the binding site 
alters the overall binding affinity.
simultaneous reversible binding  
of multiple ligands
Docking studies are a good initial method of analysis that can 
provide binding information for these complex natural prod-
ucts. These ligands can bind reversibly to H1N1 neuramini-
dase, with affinity similar to sialic acid, indicating that H1N1 
neuraminidase attack on host cells is likely to be inhibited. 
Current docking algorithms do not allow multiple-ligand 
simultaneous docking to target protein. Most natural products 
are known to have multiple active components, providing 
cumulative or synergistic effects, also overcoming buildup of 
resistance. It is highly desirable to have new molecular dock-
ing software capable of multiligand docking, for analyzing and 
understanding the mode of action of natural products.
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Possible experimental verification  
of the combination ligand hypothesis
The neuraminidase enzyme is a well studied system, and 
protocols for its expression, purification, and crystallization 
have been reported in the literature.22 The binding of multiple 
ligands could be verified by crystallizing neuraminidase in 
the presence of varying ratios of these constituents, where 
difficulties in crystallization due to high volatility would 
need to be overcome. Synthesis of the larger and probably 
less volatile biligands and triligands and their cocrystal-
lization with H1N1 neuraminidase could also be tested 
 experimentally. It is likely that some of the increased bind-
ing energy observed for biligands and triligands is due to 
increased ligand size, resulting in an increased hydrophobic 
contact surface area, so synthesis and experimental verifica-
tion of H1N1 neuraminidase binding is particularly impor-
tant to validate the potential of these ligands as drug leads. 
Alternatively, clinical evaluation would give insight into 
the benefits of these types of potential medications. Given 
that compounds like oleanolic acid, rosmarinic acid, methyl 
salicylate, menthol, and camphor are commonly used ingre-
dients with low toxicity, there would be minimal concern 
regarding safety and adverse effects during a clinical study. 
It is possible that observation and population studies would 
provide useful initial clinical information on any protective 
effect of these compounds.
Conclusion
Modeling studies of biligands and triligands, created by link-
ing methyl salicylate, menthol, and camphor via methylene 
bridges, indicate that in combination these compounds may 
be potential inhibitors of H1N1 neuraminidase. It is important 
to note, however, that high docking energies are indicative 
but not necessarily predictive of binding affinity. Therefore, 
these compounds need to be synthesized and tested experi-
mentally to determine if they in fact have high binding affinity 
for H1N1 neuraminidase.
We have shown that the strong hydrogen bond-driven 
affinity of zanamivir, sialic acid, and oseltamivir is not the 
mechanism for methyl salicylate-menthol-camphor binding. 
The hydrophobic and structural interaction of these natural 
products indicates sequential and reversible binding to H1N1 
neuraminidase. The structural and hydrophobic interactions 
of these chemical constituents offer the possibility of activity 
against H1N1 neuraminidase. By designing biligands and 
triligands, we were able to use AutoDock to study multiligand 
binding. A combination of such small molecules or these 
biligands and triligands may offer a new class of lead drug 
candidates for the prevention or treatment of influenza.
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